Capacity Bio develops small molecules, peptides, and nanoparticles that enhance the identification and clearance of dysfunctional mitochondria through the activation of mitophagy pathways. This approach addresses the accumulation of suboptimal mitochondria in cells, which contributes to increased reactive oxygen species and cell death during aging and disease.

Cyrano Therapeutics is developing CYR-064, an intranasal pharmaceutical therapy aimed at restoring olfactory function in patients experiencing chronic loss of smell and taste, particularly due to viral infections. This condition affects millions, significantly impacting quality of life, and the company is conducting a 32-week clinical trial to evaluate the safety and effectiveness of its treatment.

DIA provides a decentralized oracle platform that utilizes a rollup architecture to deliver real-time, verifiable data across over 50 blockchain networks, supporting more than 20,000 assets. This technology addresses the need for reliable and transparent data feeds in decentralized applications, enabling developers to integrate accurate price information without relying on third-party sources.

The startup develops small molecule inhibitors that target the endothelia receptor to reverse drug resistance in cancer patients undergoing immunotherapy. This approach aims to reduce tumor growth and extend survival in various cancers that are resistant to current immunotherapy treatments.

Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.

Imel Biotherapeutics is developing a mitochondrial replacement therapy that enhances T cell functionality by replacing dysfunctional mitochondria with healthy ones, achieving over 90% mitochondrial replacement. This approach targets T cell exhaustion in elderly cancer patients, improving their immune response and potential treatment outcomes.

Immunis is a biotechnology company developing IMM01-STEM, a biologic therapy that utilizes natural human immune modulators to enhance muscle regeneration and metabolism. The company is conducting a Phase 1/2a clinical trial to evaluate the therapy's effectiveness in treating age-related muscle atrophy.

Kupando is a Berlin-based biopharmaceutical company developing TLR 4/7 agonists that activate the innate immune system to treat solid tumors and prevent infectious diseases. Their drug candidates offer a cost-effective immunotherapy solution with high specificity and potency, addressing the need for effective treatments in oncology and infectious disease prevention.

LUCA Science develops targeted gene therapies to restore mitochondrial function in patients with mitochondrial diseases. The company focuses on providing effective treatment options in a field with limited alternatives, aiming to enhance patient outcomes and quality of life.

The startup offers an automatic bill-splitting application that utilizes a shared digital wallet and electronic payment systems to facilitate simultaneous group payments. Users can pay a single bill while the platform automatically divides the costs among participants, eliminating the hassle of manual calculations and transactions.

Multimedia streaming marketplace connecting content creators with consumers through a platform that facilitates the distribution and monetization of digital media. It addresses the challenges of content discovery, licensing, and revenue generation in a fragmented digital landscape.

Phostin Therapeutics develops First-In-Class Glycocalyx Modifiers that target glycosylation mechanisms to enhance immune response against aggressive solid tumors. Their Glycosylation inhibitors aim to reduce tumor invasiveness and improve treatment outcomes for cancers and other serious diseases.

Restore Vision is developing a gene therapy specifically targeting retinitis pigmentosa, a genetic disorder that leads to progressive vision loss. This therapy aims to restore visual function by addressing the underlying genetic causes of the disease.

Technol designs and manufactures eco-friendly machinery that significantly reduces the time required for crop collection through advanced automation techniques. This technology addresses the inefficiencies in traditional harvesting methods, enabling farmers to increase productivity and minimize labor costs.

Tranquis Therapeutics is developing small molecule drugs that reprogram dysfunctional immune cells to restore mitochondrial and lysosomal function, targeting neurodegenerative and aging-related diseases. Their therapies aim to improve cellular homeostasis, potentially transforming the treatment landscape for a range of central nervous system and non-central nervous system conditions.

Up is a direct-to-consumer smart home appliance brand that offers an AI cooking assistant capable of automating over 16 cooking functions, including chopping and stirring, using a patented Omni Blade technology. This appliance addresses the challenge of meal preparation by providing step-by-step guidance through an 8-inch touchscreen and a mobile app, enabling users to cook a variety of recipes with minimal manual intervention.

Viage Therapeutics develops DGX-001, a first-in-class oral neurotherapeutic that modulates the vagus nerve through receptor interactions on enteroendocrine cells in the gut, targeting cognitive impairment in conditions like Alzheimer's and Parkinson's disease. The drug's gut-restricted mechanism minimizes systemic exposure and potential side effects, offering a safer alternative to traditional psychiatric medications.